Risk Factors Update Summary
- CEO transition: New CEO Charles S. McKhann succeeded Erica J. Rogers, impacting leadership stability.
- Increased reliance on Cordis for ENROUTE stent supply, with Cordis as the sole supplier.
- Loss of institutional knowledge: Departure of former CEO Erica J. Rogers may affect operations.
- Provisions in our bylaws and certificate of incorporation could limit voting power and acquisition prices.
- Expansion of sales and marketing infrastructure causing revenue disruption, affecting revenue through H1 2024.
- Financial risks: Recent significant decline in long-term incentives may impact key employee retention.
- Delaware law Section 203 restricts business combinations with interested stockholders for three years.
- Concerns about supply chain constraints affecting manufacturing delays for TCAR products.
- Disputes between us and stockholders are exclusively resolved in the Delaware Court of Chancery.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1397702&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.